Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ascendis Pharma A/S - American Depositary Shares
(NQ:
ASND
)
235.38
+1.88 (+0.81%)
Streaming Delayed Price
Updated: 1:03 PM EST, Mar 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ascendis Pharma A/S - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Ascendis (ASND) Q4 2025 Earnings Call Transcript
↗
February 23, 2026
Ascendis (ASND) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million
↗
February 22, 2026
Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
↗
February 22, 2026
Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.
Via
The Motley Fool
Ascendis Pharma (NASDAQ:ASND) Shares Drop After Q4 Earnings Miss on Wider-Than-Expected Loss
↗
February 11, 2026
Via
Chartmill
Topics
Earnings
ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum
↗
January 28, 2026
Via
Chartmill
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction
↗
February 22, 2026
Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.
Via
The Motley Fool
Topics
Regulatory Compliance
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges
↗
February 22, 2026
Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.
Via
The Motley Fool
Topics
Regulatory Compliance
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript
↗
February 11, 2026
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript
Via
The Motley Fool
Earnings Scheduled For November 12, 2025
↗
November 12, 2025
Via
Benzinga
A Look Ahead: Ascendis Pharma's Earnings Forecast
↗
November 11, 2025
Via
Benzinga
How Do Investors Really Feel About Ascendis Pharma?
↗
August 28, 2025
Via
Benzinga
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
Ascendis Pharma (NASDAQ:ASND) Passes Minervini's Trend Template and High Growth Momentum Scan
↗
December 25, 2025
Ascendis Pharma (ASND) meets Mark Minervini's strict criteria, showing a powerful technical uptrend paired with explosive revenue growth over 269%.
Via
Chartmill
Why Dyne Therapeutics Stock Was Crushing it This Week
↗
November 21, 2025
The company has solid potential with its development of drugs targeting muscle disorders.
Via
The Motley Fool
Topics
Artificial Intelligence
European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility
November 19, 2025
European American Depositary Receipts (ADRs) have recently experienced a period of significant fluctuation, reflecting a broader climate of market volatility that has ripple across global financial...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Supply Chain
Ascendis (ASND) Q3 2025 Earnings Call Transcript
↗
November 13, 2025
Ascendis (ASND) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
↗
November 12, 2025
Via
Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
↗
October 29, 2025
Via
Benzinga
Looking Into Ascendis Pharma AS's Recent Short Interest
↗
October 21, 2025
Via
Benzinga
Ascendis Pharma A/S - ADR (NASDAQ:ASND) Shows Strong Growth Momentum in Technical and Fundamental Analysis
↗
October 14, 2025
Ascendis Pharma (ASND) is a high-growth stock with strong technical uptrends and impressive fundamentals, including surging revenue and earnings momentum.
Via
Chartmill
What Does the Market Think About Ascendis Pharma AS?
↗
September 29, 2025
Ascendis Pharma AS's (NYSE: ASND) short interest as a percent of float has fallen 14.63% since its last report. According to exchange reported data, there are now 2.29 million shares sold short, which...
Via
Benzinga
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
↗
September 25, 2025
Ascendis Pharma (NASDAQ: ASND) has outperformed the market over the past 10 years by 13.64% on an annualized basis producing an average annual return of 26.77%. Currently, Ascendis Pharma has a market...
Via
Benzinga
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment
↗
September 08, 2025
BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study.
Via
Benzinga
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
↗
September 08, 2025
Via
Benzinga
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
↗
September 04, 2025
Via
Benzinga
ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Technical Strength and High-Growth Momentum
↗
September 01, 2025
Ascendis Pharma (ASND) excels in both technical & fundamental momentum, meeting Minervini's Trend Template criteria for high-growth stocks poised for potential outperformance.
Via
Chartmill
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
↗
August 19, 2025
Via
Benzinga
Ascendis (ASND) Q2 2025 Earnings Call Transcript
↗
August 07, 2025
Via
The Motley Fool
Topics
Earnings
What's Driving the Market Sentiment Around Ascendis Pharma?
↗
August 06, 2025
Via
Benzinga
What's Driving the Market Sentiment Around Ascendis Pharma?
↗
August 04, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
